These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. Cotter G; Dittrich HC; Weatherley BD; Bloomfield DM; O'Connor CM; Metra M; Massie BM; J Card Fail; 2008 Oct; 14(8):631-40. PubMed ID: 18926433 [TBL] [Abstract][Full Text] [Related]
4. Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure - Post-hoc analysis of the PROTECT trial. Demissei BG; Postmus D; Liu LCY; Cleland JG; O'Connor CM; Metra M; Ponikowski P; Teerlink JR; Cotter G; Davison BA; Edwards C; Givertz MM; Bloomfield DM; Dittrich HC; Voors AA; Hillege HL Int J Cardiol; 2016 Nov; 223():967-975. PubMed ID: 27589047 [TBL] [Abstract][Full Text] [Related]
5. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function). Voors AA; Dittrich HC; Massie BM; DeLucca P; Mansoor GA; Metra M; Cotter G; Weatherley BD; Ponikowski P; Teerlink JR; Cleland JG; O'Connor CM; Givertz MM J Am Coll Cardiol; 2011 May; 57(19):1899-907. PubMed ID: 21545947 [TBL] [Abstract][Full Text] [Related]
6. Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. Metra M; O'Connor CM; Davison BA; Cleland JG; Ponikowski P; Teerlink JR; Voors AA; Givertz MM; Mansoor GA; Bloomfield DM; Jia G; DeLucca P; Massie B; Dittrich H; Cotter G Eur Heart J; 2011 Jun; 32(12):1519-34. PubMed ID: 21388992 [TBL] [Abstract][Full Text] [Related]
7. Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function. Weatherley BD; Cotter G; Dittrich HC; DeLucca P; Mansoor GA; Bloomfield DM; Ponikowski P; O'Connor CM; Metra M; Massie BM; J Card Fail; 2010 Jan; 16(1):25-35. PubMed ID: 20123315 [TBL] [Abstract][Full Text] [Related]
8. Haemodynamic effects of rolofylline in the treatment of patients with heart failure and impaired renal function. Ponikowski P; Mitrovic V; O'Connor CM; Dittrich H; Cotter G; Massie BM; Givertz MM; Chen E; Murray M; Weatherley BD; Fujita KP; Metra M Eur J Heart Fail; 2010 Nov; 12(11):1238-46. PubMed ID: 20823097 [TBL] [Abstract][Full Text] [Related]
9. The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. Givertz MM; Massie BM; Fields TK; Pearson LL; Dittrich HC; J Am Coll Cardiol; 2007 Oct; 50(16):1551-60. PubMed ID: 17936154 [TBL] [Abstract][Full Text] [Related]
10. Rolofylline: a selective adenosine 1 receptor antagonist for the treatment of heart failure. Slawsky MT; Givertz MM Expert Opin Pharmacother; 2009 Feb; 10(2):311-22. PubMed ID: 19236201 [TBL] [Abstract][Full Text] [Related]
11. A single supratherapeutic dose of rolofylline does not prolong the QTcF interval in healthy volunteers. Radziszewski W; Lai E; Lazarus Shipitofsky N; Stroh M; Dishy V; Han L; Lewis W; Johnson-Levonas AO; Lutz R; Wagner J Am J Ther; 2010; 17(1):8-16. PubMed ID: 20027105 [TBL] [Abstract][Full Text] [Related]
12. The effects of multiple doses of rolofylline on the single-dose pharmacokinetics of midazolam in healthy subjects. Stroh M; Dishy V; Radziszewski W; Hwang E; Lazarus-Shipitofsky N; Dittrich H; Johnson-Levonas AO; Lutz R; Wagner JA; Lai E Am J Ther; 2010; 17(1):53-60. PubMed ID: 20027108 [TBL] [Abstract][Full Text] [Related]
13. Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) Study. Cleland JG; Chiswell K; Teerlink JR; Stevens S; Fiuzat M; Givertz MM; Davison BA; Mansoor GA; Ponikowski P; Voors AA; Cotter G; Metra M; Massie BM; O'Connor CM Circ Heart Fail; 2014 Jan; 7(1):76-87. PubMed ID: 24281134 [TBL] [Abstract][Full Text] [Related]
14. The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. Dittrich HC; Gupta DK; Hack TC; Dowling T; Callahan J; Thomson S J Card Fail; 2007 Oct; 13(8):609-17. PubMed ID: 17923351 [TBL] [Abstract][Full Text] [Related]
15. Simultaneous pharmacokinetic model for rolofylline and both M1-trans and M1-cis metabolites. Stroh M; Hutmacher MM; Pang J; Lutz R; Magara H; Stone J AAPS J; 2013 Apr; 15(2):498-504. PubMed ID: 23355301 [TBL] [Abstract][Full Text] [Related]
16. International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial. Mentz RJ; Cotter G; Cleland JG; Stevens SR; Chiswell K; Davison BA; Teerlink JR; Metra M; Voors AA; Grinfeld L; Ruda M; Mareev V; Lotan C; Bloomfield DM; Fiuzat M; Givertz MM; Ponikowski P; Massie BM; O'Connor CM Eur J Heart Fail; 2014 Jun; 16(6):614-24. PubMed ID: 24771609 [TBL] [Abstract][Full Text] [Related]
17. Renal function trajectories and clinical outcomes in acute heart failure. Givertz MM; Postmus D; Hillege HL; Mansoor GA; Massie BM; Davison BA; Ponikowski P; Metra M; Teerlink JR; Cleland JG; Dittrich HC; O'Connor CM; Cotter G; Voors AA Circ Heart Fail; 2014 Jan; 7(1):59-67. PubMed ID: 24281137 [TBL] [Abstract][Full Text] [Related]
18. Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure. Ter Maaten JM; Valente MA; Damman K; Cleland JG; Givertz MM; Metra M; O'Connor CM; Teerlink JR; Ponikowski P; Bloomfield DM; Cotter G; Davison B; Subacius H; van Veldhuisen DJ; van der Meer P; Hillege HL; Gheorghiade M; Voors AA Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27266853 [TBL] [Abstract][Full Text] [Related]
19. Worsening Heart Failure Following Admission for Acute Heart Failure: A Pooled Analysis of the PROTECT and RELAX-AHF Studies. Davison BA; Metra M; Cotter G; Massie BM; Cleland JGF; Dittrich HC; Edwards C; Filippatos G; Givertz MM; Greenberg B; Ponikowski P; Voors AA; O'Connor CM; Teerlink JR; JACC Heart Fail; 2015 May; 3(5):395-403. PubMed ID: 25951761 [TBL] [Abstract][Full Text] [Related]
20. Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality. Beusekamp JC; Tromp J; Cleland JGF; Givertz MM; Metra M; O'Connor CM; Teerlink JR; Ponikowski P; Ouwerkerk W; van Veldhuisen DJ; Voors AA; van der Meer P JACC Heart Fail; 2019 Nov; 7(11):970-979. PubMed ID: 31606364 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]